Form 4: Eledon Pharmaceuticals Director Keith Katkin Acquires Stock Options and Restricted Stock Units

Eledon Pharmaceuticals director Keith Katkin was granted stock options for 77,175 shares and 8,575 restricted stock units on January 10, 2025.

Summary

• Keith Katkin, a director at Eledon Pharmaceuticals, acquired stock options for 77,175 shares of common stock at an exercise price of $4.04 per share.
• These options vest 100% on January 10, 2026, and expire on January 10, 2035.
• Katkin also received 8,575 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock upon settlement.
• These RSUs also vest 100% on January 10, 2026.
• The transactions were reported on a Form 4 filing with the SEC.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of equity compensation for a director, which is generally viewed positively as it aligns interests. There are no negative implications or surprises.

Positives

• The grant of stock options and restricted stock units to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Eledon Pharmaceuticals' stock price.
• There is a risk that the stock price may not reach a level that makes the options valuable to the director.

Future Outlook

The document does not contain any forward-looking statements about the company's future performance.

Industry Context

The granting of stock options and restricted stock units is a common practice for incentivizing directors and aligning their interests with shareholders in the pharmaceutical industry.

Comparison to Industry Standards

• Stock option and RSU grants are standard practice for compensating directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Vesting schedules, such as the one-year cliff vesting in this case, are also common to ensure long-term commitment.
• The specific number of shares and exercise price are company-specific and depend on various factors, including the company's valuation and compensation policies.

Stakeholder Impact

• The grant of stock options and RSUs could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
• The vesting schedule encourages the director to remain committed to the company.

Key Dates

Keywords

Eledon Pharmaceuticals, stock options, restricted stock units, insider trading, Form 4, equity compensation, Keith Katkin, director